Acalabrutinib and Isavuconazole: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A inhibition alters acalabrutinib and active-metabolite exposure.
Clinical significance and safety
When Acalabrutinib and Isavuconazole are used together, monitor closely for acalabrutinib adverse effects. The current EMA product information does not require an automatic dose adjustment for a moderate CYP3A inhibitor, despite changes in parent-drug and metabolite exposure. The treatment team should apply the product information relevant to the actual medicine and clinical situation.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.